Clinical Trials · NCT00676338
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 820
- Start date
- Nov 2008
- Locations
- 106 sites, 22 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 26